Increased risk of colorectal neoplasia in patiets with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis

Gastrointestinal Endoscopy

Volumn 56, Issue 1, 2002, Pages 48-54

  Soetikno, Roy M ^a,b   Lin, Otto S ^a,b   Heidenreich, Paul A ^a,b   Young, Harvey S ^a,b   Blackstone, Michael O ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; HUMAN; META ANALYSIS; PRECANCER; RISK; RISK FACTOR; SCLEROSING CHOLANGITIS; ULCERATIVE COLITIS; ANEUPLOIDY; CANCER DIAGNOSIS; CANCER RISK; COLONOSCOPY; COLORECTAL CARCINOMA; DISEASE COURSE; DYSPLASIA; ENTERITIS; HISTOPATHOLOGY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; HUMANS; ODDS RATIO; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 0036637281     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1067/mge.2002.125367     Document Type: Article

References (45)

1. Broomé U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis - a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992;102:1877-80.
2. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33.
3. Ekbom A, Helmick C, Zack M, Adanii HO. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med 1990;323:1228-33.
4. Ahnen DJ, McHugh JBD, Arsenault LL, Warren G. Does primary sclerosing cholangitis (PSC) increase the risk of colon cancer in patients with chronic ulcerative colitis (CUC) [abstract]? Gastroenterology 1993;104:A658.
5. Broomi U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
6. Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996;110:331-8.
7. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996;91:44-8.
8. Shetty K, Rybicki L, Brzezinski A, Carey WD, Lashner BA. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999;94:1643-9.
9. Marchesa P, Lashner BA, Lavery IC, Milsom J, Hull TL, Strong SA, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997;92:1285-8.
10. Leidenius MH, Farkkila MA, Karkkainen P, Taskinen EI, Kellokumpu IH, Hockerstedt KA. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis. Scan J Gastroenterol 1997;32:706-11.
11. Timmermanns G, Heuschen UA, Stern J, Herfath CH. Enhanced colorectal cancer risk in patients with ulcerative colitis associated with PSC [abstract]. Gastroenterology 1996;110:A603.
12. Loftus EV, Sandborn WJ, Tremaine WJ, Mahoney DW, Zinsmeister AR, Offord KP, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996;110:432-40.
13. Choi PM, Nugent FW, Rossi RL. Relationship between colorectal neoplasia and primary sclerosing cholangitis in ulcerative colitis. Gastroenterology 1992;103:1707-9.
14. Aadland E, Schrunpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987;22:655-64.
15. Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol 2000;95:2710-9.
16. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of folio acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32.
17. Ransohoff DF. Colorectal cancer. In: Everhart YE, editor. Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, Public Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government Printing Office; 1994. NIH publication no. 94-1447.
18. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego: Academic Press; 1985.
19. Petitti DB. Meta-analysis decision analysis and cost-effectiveness analysis. Methods for quantitative synthesis in medicine. New York: Oxford University Press; 1994.
20. Higashi H, Yanaga K, Marsh JW, Tzakis A, Kakizoe S, Starzl TE. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology 1990;11:477-80.
21. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993;36:908-12.
22. Gurbuz AK, Giardiello FM, Bayless TM. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Dis Colon Rectum 1995;38:37-41.
23. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993;88:1174-8.
24. Narumi S, Roberts JP, Emond JC, Lake J, Asoher NL. Liver transplantation for sclerosing cholangitis. Hepatology 1995;22:451-7.
25. Pinczowski D, Ekjbom A. Is there an increased risk of colorectal cancer among ulcerative colitis patients with primary sclerosing cholangitis [abstract]? Gastroenterology 1995;108: A29.
26. Shaked A, Colonna JO, Goldstein L, Busuttil RW. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992;215:598-603.
27. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study. Cancer 1998;82:822-6.
28. Kornfeld D, Ekbom A, Ihre T. Is there an excessive risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41:522-5.
29. Kingham JG. Risk of colon cancer in patients with ulcerative colitis is potentiated by the presence of primary sclerosing cholangitis. Hepatology 1997;25:254.
30. Loftus EV Jr, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RA, Zinsmeister AR, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998;27:685-90.
31. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol Bull 1979;86:638-41.
32. Stiehl A, Rudolph G, Sauer P, Theilmann L. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis: influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995;23:283-9.
33. Tung BY, Emond MH, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
34. Hawk ET, Viner IL. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med 2001;134:158-60.
35. Blackstone MO. An association of fecal bile acids and colon cancer in ulcerative colitis? Gastroenterology 1988;95:575-6.
36. Siegel JH, Barnes S, Morris JS. Bile acids in liver disease associated with inflammatory bowel disease. Digestion 1977;15:469-81.
37. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31-9.
38. van Milligen de Wit AW, van Deventer SJ, Tytgat GN. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995;90:893-900.
39. Ilyas M, Talbot IC. p53 Expression in ulcerative colitis: a longitudinal study. Gut 1995;37:802-4.
40. Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of p53 allele. Gastroenterology 1992;103:1602-10.
41. Itzkowitz SH, Young E, DuBois D, Harpaz N, Bodian C, Chen A, et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Gastroenterology 1996;110:694-704.
42. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994;107:532-6.
43. Broomé U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994;35:84-9.
44. Lebovics E, Palmer M, Woo J, Schaffner F. Outcome of primary sclerosing cholangitis. Arch Intern Med 1987;147:729-31.
45. Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994;69:969-82.